Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

Australia's CSL agrees to buy Novartis’ influenza vaccine business for $275m Australian biotechnology firm CSL has agreed to acquire Novartis’ global influenza vaccine business for $275m, a move that will make it the world's second-largest flu vaccine maker. Drug Research > Drug Delivery > News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

EMA advises GSK on Ebola vaccine development plan
The European Medicines Agency (EMA) has given scientific advice to GSK on its development plan for an Ebola vaccine.
News
Triphase, Celgene extend deal for IV formulation of marizomib and bevacizumab for glioblastoma
By PBR Staff Writer
Drug development firm Triphase Accelerator has extended its strategic collaboration with Celgene for a Phase I development program to explore combining an intravenous (IV) formulation of marizomib with bevacizumab in glioblastoma (GBM), an aggressive malignant primary brain tumor.
News

Drug Discovery & Development

MEI Pharma begins dosing in ME-344 Phase Ib trial for small cell lung and ovarian cancers
By PBR Staff Writer
US-based MEI Pharma has dosed the first patient in a cohort-expansion stage of its Phase Ib clinical trial of ME-344 in combination with topotecan to treat patients with small cell lung or ovarian cancer who failed initial therapy.
News
Relmada adds $15m in capital to accelerate development of pain treatment drugs
Relmada Therapeutics, a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline, has received a healthy injection of more than $15m in capital last week that will assist the company in the advancement of its work to bring those products to the largest drug prescription market in the world - the treatment of pain.
News